Download PDF
Thromb Haemost 2008; 99(04): 782-783
DOI: 10.1160/TH07-07-0456
Case Report
Schattauer GmbH

Rituximab failure in a patient with monoclonal gammopathy of undetermined significance (MGUS)- associated acquired von Willebrand syndrome

David Grimaldi
1   Service de Médecine interne
,
Pablo Bartolucci
1   Service de Médecine interne
,
Michele Gouault-Heilmann
2   Service d'Hématologie Biologique, Hôpital Henri Mondor, Créteil cedex, France
,
Isabelle Martin-Toutain
3   Service d'Hématologie Biologique, Groupe Hospitalier Pitié-Salpetrière Paris, Paris Cedex, France
,
Mehdi Khellaf
1   Service de Médecine interne
,
Bertrand Godeau
1   Service de Médecine interne
› Author Affiliations
Further Information

Publication History

Received: 17 July 2007

Accepted after major revision: 01 March 2008

Publication Date:
25 November 2017 (online)

Also available at
    Permissions and Reprints

 

 

  • References

  • 1 Federici AB. Use of intravenous immunoglobulin in patients with acquired von Willebrand syndrome. Hum Immunol 2005; 66: 422-430.
    CrossrefPubMedSearch in Google Scholar
  • 2 Stasi R, Brunetti M, Stipa E. et al. Selective B-cell depletion with rituximab for the treatment of patients with acquired hemophilia. Blood 2004; 103: 4424-4428.
    CrossrefPubMedSearch in Google Scholar
  • 3 Michiels JJ, Budde U, van der Planken M. et al. Acquired von Willebrand syndromes: clinical features, aetiology, pathophysiology, classification and management. Best Pract Res Clin Haematol 2001; 14: 401-436.
    CrossrefPubMedSearch in Google Scholar
  • 4 Federici AB, Rand JH, Bucciarelli P. et al. Acquired von Willebrand syndrome: data from an international registry. Thromb Haemost 2000; 84: 345-349.
    Thieme ConnectPubMedSearch in Google Scholar
  • 5 Mohri H, Motomura S, Kanamori H. et al. Clinical significance of inhibitors in acquired von Willebrand syndrome. Blood 1998; 91: 3623-3629.
    PubMedSearch in Google Scholar
  • 6 Coleman R, Favaloro EJ, Soltani S. et al. Acquired von Willebrand disease: potential contribution of the VWF:CB to the identification of functionally inhibiting autoantibodies to von Willebrand factor. J Thromb Haemost 2006; 4: 2085-2088.
    CrossrefPubMedSearch in Google Scholar
  • 7 Smaradottir A, Bona R. A case of acquired von Willebrand syndrome successfully treated with recombinant Factor VIIa during thyroidectomy. Thromb Haemost 2004; 92: 666-667.
    Thieme ConnectPubMedSearch in Google Scholar
  • 8 Michiels JJ, Berneman Z, Gadisseur A. et al. Immune-mediated etiology of acquired von Willebrand syndrome in systemic lupus erythematosus and in benign monoclonal gammopathy: therapeutic implications. Semin Thromb Hemost 2006; 32: 577-588.
    Thieme ConnectPubMedSearch in Google Scholar
  • 9 Macik BG, Gabriel DA, White GC. et al. The use of high-dose intravenous gammaglobulins in acquired von Willebrand’s syndrome. Arch Pathol Lab Med 1988; 112: 143-146.
    PubMedSearch in Google Scholar
  • 10 Agarwal N, Klix MM, Burns CP. Successful management with intravenous immunoglobulins of acquired von Willebrand disease associated with monoclonal gammopathy of undetermined significance. Ann Intern Med 2004; 141: 83-84.
    CrossrefPubMedSearch in Google Scholar
  • 11 Scrobohaci ML, Daniel MT, Levy Y. et al. Expression of GpIb on plasma cells in a patient with monoclonal IgG and acquired von Willebrand disease. Br J Haematol 1993; 84: 471-475.
    CrossrefPubMedSearch in Google Scholar